Abstract
Endoscopic retrograde cholangiopancreatography (ERCP) is becoming more common than first‐line therapy for pancreaticobiliary duct disorders. However, post‐ERCP pancreatitis is the most common complication of ERCPs, and affects about 10% of cases. In this review, we provide an overview of the mechanisms purported to cause post‐ERCP pancreatitis as well as associated risk factors. We discuss measures that are in practice for post‐ERCP pancreatitis pharmaco‐prophylaxis, along with advances in the pipeline. We emphasize that there is still a pressing need to narrow the incidence of post‐ERCP pancreatitis and that a mechanistic approach may reveal the greatest benefit from utilizing a combination of targets.

This publication has 85 references indexed in Scilit: